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ABSTRACT 
Breast cancer is the leading cause of death among women and is highly heterogeneous in 
nature. One very aggressive subtype of this disease is Triple Negative Breast Cancer. Triple 
Negative Breast Cancer (TNBC), is a very aggressive disease characterized by the lack of 
expression of estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth 
factor receptor-2 (HER-2).  TNBC patients account for approximately 15% of total breast cancer 
patients. This breast cancer subtype is characterized by high mortality rate, and is typically 
associated with poor prognosis. Current clinical methods have proven to have low success rates 
against TNBC, it is proposed that prevention by dietary approach with naturally occurring 
compounds in foods will be more effective. The objective of this research was to study the 
inhibitory activity of black seed oil and potassium chloride against the biomarkers of triple 
negative breast cancer.  Hormone-independent MDA-MB-231 breast cancer cells were incubated 
with black seed oil, potassium chloride, or the combination of black seed oil with potassium 
chloride and incubated at 37 ºC and 5% CO2 in a humidified incubator for 24, 48, or 72 h. Cell 
viability was measured by MTS assay. The effect of black seed oil on angiogenesis was 
determined using in vitro angiogenesis tube formation assay. Cancer cell cycle was analyzed by 
flow cytometry. The expression levels of biomarkers of TNBC cells were evaluated by Western 
blots. This study showed that black seed oil and potassium chloride proved efficient in down-
regulating TNBC associated biomarkers including ALDH1, CD44, ESA, PI3K/Akt, Erk, COX-2, 
NFκB, Hsp90, p53, p21, Bax, and Bcl-2. The results indicate that black seed oil or KCl or their 
combination can attenuate the biomarkers of triple negative breast cancer MDA-MB-231, 
suggesting a potential preventive role against the disease.
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CHAPTER 1: 
INTRODUCTION 
Breast cancer is the second most common cancer in the world and most common cancer 
among women (Key and others 2003).  It is a leading cause of death in women and this disease is 
highly heterogeneous in nature. Triple Negative Breast Cancer (TNBC), which is a subtype of 
inflammatory breast cancer, is a very aggressive disease with poor prognosis. The malfunction in 
the DNA repair process leading to increased apoptosis and defective cell cycle, contributes to the 
poor prognosis of this disease. 
The disease is characterized by a lack of targeted therapies, and is highly chemo-
sensitive. There are current challenges faced by chemotherapy treatment for this disease, such as 
a lack of established targets, resulting in its low success rate. With the still unmet responses to 
the challenges of this disease, there arises strong need for more efficacious treatment options. 
The poor prognosis and low success rates of treatments associated with triple negative breast 
cancer implies that prevention by dietary approach would be better, thus the use of non-toxic 
naturally occurring bioactive compounds may be more effective and may be the best approach in 
targeting this disease.  
Sustained angiogenesis is one of the known hallmarks of cancer. Angiogenesis is the 
formation of new blood vessels from pre-existing ones. It is a process that occurs normally in life 
but also plays a role in various disease conditions when there is an imbalance in the regular 
process of angiogenic stimulation and inhibition. The process of angiogenesis advances tumor 
growth and metastasis by the disruption of basement membrane of endothelial cells, cell 
proliferation, migration, and finally formation of new three dimensional tubular structures. 
Targeting angiogenic factors is one of the major approaches to cancer treatment and prevention. 
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It is well established that there are various mechanisms which may lead to an increased 
risk of breast cancer due to its inherent heterogeneity. One major risk factor is proved by the 
evidence that nutritional factors can affect breast cancer risk either positively or negatively 
through hormonal mechanisms; For example, saturated fat can pose negative risk (Key and 
others 2003).  It is proposed that dietary bioactive compounds will carry out inhibitory activities 
against the growth and metastasis of cancerous cells without affecting normal breast cells. This 
will result in better patient treatment outcomes including the prevention of relapse, moreover 
improving prognosis, and ultimately increasing overall survival rates (Altenburg and others 
2011; George and others 2011). Prevention has been recognized by world top oncologists as the 
best cure for cancer, food can prevent cancer from progressing and causing death.  
Dietary bioactive compounds that promote cancer inhibition have been identified and 
studied. Some of which include curcumin, epigallocatechin, resveratrol, diosgenin, 
thymoquinone, etc. The focus for this study was black seed oil, extracted from black seed also 
known as black cumin seed, or Nigella Sativa. The main bioactive component in black seed oil is 
thymoquinone which has been found to possess inhibitory properties against cancer cell 
proliferation, and to induce apoptosis in various human cancers (Gali-Muhtasib and others 2006). 
The main objective of this study was to investigate the interaction of black seed oil 
(BSO) or potassium chloride (KCl) or a combination of the oil with potassium chloride with the 
biomarkers of triple negative breast cancer. The steps taken to test this objective include: 
1) Investigation of the cancer cell viability after treatments with BSO, KCl and the 
combination of both treatments.  
2) Analyses on the effects of the treatments on cell cycle, angiogenesis, and signal 
transduction pathways associated with TNBC  
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CHAPTER 2: 
LITERATURE REVIEW 
2.1. Breast Cancer  
Breast cancer is a complex disease which is heterogeneous in nature (Bosch and others 
2010; Oakman and others 2010), with diverse outcomes and responses to treatment (Oakman and 
others 2010). It is the most common diagnosed malignancy in women (Giovannini and others 
2010). It is the most common cancer in women and the leading cause of death (Irminger-Finger 
2010; Irvin Jr and Carey 2008). The statistics in 2007 show that 1,300,000 women were 
diagnosed with breast cancer and 465,000 died from breast cancer worldwide. In the United 
States, 182,480 new diagnoses and 40,170 deaths were estimated in 2009 (Sun and others 2010). 
The American Cancer Society (ACS) estimated 207,090 new cases of invasive breast cancer 
diagnosis in women and 39,840 deaths for 2010. The trends show an increase in breast cancer 
diagnoses. 
Various risk factors influence the development of breast cancer such as age, gender, race, 
dietary and life-style habits, physical activity, and breast cancer susceptibility gene mutation 
carriers (Tot 2011). Breast cancer cells have the ability to metastasize and spread to other sites in 
the body. One major way this occurs is through the lymphatic system. Most of the lymph vessels 
lead to axillary lymph nodes located under the arms (see Figure 2.1). The cells can enter the 
lymphatic vessels and begin to grow in lymph nodes and cause the lymph nodes to swell. There 
is higher likelihood that cancerous cells will be found in the blood stream and other parts of the 
body once the cancerous cells get into the axillary lymph nodes and if there are more lymph 
nodes with cancer cells (Cancer 2010).  The many different types of breast cancer mainly 
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constitute of about 80% invasive ductal carcinomas, and 10-15% invasive lobular carcinomas 
while the rest (5-10%) are the additional rare types (Hwang-Verslues and others 2009). 
                             
Figure 2.1: The Lymphatic system 
Breast cancer has been defined and classified using a number of clinical and pathologic 
features (such as age, tumor size, hormonal receptor status, etc) for outcome predictions and 
response to treatment (Bosch and others 2010; Irvin Jr and Carey 2008). A validated classification 
based on gene-expression assays considered four breast cancer subtypes (Table 2.1.) The classes 
include: luminal, human epidermal growth factor receptor (HER2 or ERBB2) positive, normal 
breast, and basal like (Bosch and others 2010; Hwang-Verslues and others 2009).  
Table 2.1: Breast cancer classification based on gene-expression 
Breast Cancer Subtype          Characteristics 
Luminal High expression of many genes expressed by breast luminal cells 
cytokeratins (8/18)and estrogen receptors  
Does not overexpress ERBB2. 
ERBB2 + Overexpression of ERBB2 oncogene 
Low levels of estrogen receptor (ER) expressions and all genes 
associated with it. 
Normal breast subtype Expression of genes distinctive of basal epithelial and adipose cells 
Low expression of luminal cells gene clutter 
Basal-like High expression of cytokeratin 5/6 and 17, fatty acid binding protein7 
Failure to express ER and most genes co-expressed with it 
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Breast cancer is also classified based on clinical manifestations such as inflammatory and 
non-inflammatory breast cancer. The highly aggressive form, inflammatory breast cancer, was 
the main focus for this study and will be discussed in more detail.  
2.2. Inflammatory Breast Cancer  
A discrete clinical and pathologic entity with rapid disease progression and poor 
prognosis describe a form of breast cancer among the most metastatic variants of breastcancer 
known as inflammatory breast cancer (IBC) (Cariati and others 2005; Lopez and Porter 1996). 
Though IBC represents less than 10% of all breast cancers, it is the most lethal form of the 
disease (Ben Hamida and others 2008).  The lethality of IBC is ascribed to its high invasive 
nature (Hoffmeyer and others 2005).  
The American Joint Committee on Cancer (AJCC) defines IBC as “a clinicopathologic 
entity characterized clinically by diffuse edema and erythema of the breast, over the majority of 
the breast, and often without an underlying mass. The clinical appearance is due to pathologic 
plugging of the dermal lymphatics of the breast, but pathologic involvement of the dermal 
lymphatics alone does not confirm the diagnostics” (Anderson and others 2005) . 
The main features that distinguish inflammatory breast cancer from other forms of breast 
cancer are its distinct phenotype, which includes rapidly progressive breast inflammation, and a 
high tendency for metastasis to occur (Lerebours and others 2008; Zell and others 2009). This 
suggests a high propensity for tumor cells to migrate (Ben Hamida and others 2008). The 
survival rate is significantly different from the non-inflammatory forms of breast cancer: a 3-yr 
survival rate is about 40% compared to non-inflammatory breast cancers with 85% (Lerebours 
and others 2008).  
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Inflammatory-like symptoms such as redness, warmth, and edema prevent proper 
diagnosis of the disease. A change in breast skin texture with similarities to that of an orange 
peel is a characteristic of IBC (Hoffmeyer and others 2005). This does not occur as a result of 
true physiologic inflammatory response (Anderson and others 2005). It is due, rather to extensive 
invasion of the dermal lymphatics by IBC tumor cell emboli (Anderson and others 2005; 
Hoffmeyer and others 2005). Thus, by the time proper diagnosis is made, the cancer would have 
aggressively filtered through surrounding tissues and the lymphatic system, leading to poor 
prognosis (Hoffmeyer and others 2005).            
The descriptions of several molecular alterations in IBC include frequent hormone 
receptor negativity, TP53 mutations and HER2 amplifications (Lerebours and others 2008). Most 
studies have focused on the role of estrogen and progesterone receptors for investigations on the 
molecular basis of IBC. The majority of IBCs are estrogen receptor negative (Cariati and others 
2005). 
2.3.Triple Negative Breast Cancer  
A lack in the expression of estrogen receptors (ER), progesterone receptors (PR) and 
human epidermal growth factor receptor-2 (HER-2) results in an aggressive type of cancer 
referred to as Triple Negative Breast Cancer (TNBC) (Carotenuto and others 2010; Chen and 
Russo 2009; Liedtke and others 2008; Oakman and others 2010; Podo and others 2010). TNBC 
accounts for approximately 25% of the total breast cancer population, and mostly occurs in 
young women originating from African, African-American, and Latino ethnic groups 
(Carotenuto and others 2010; Chen and Russo 2009). This type of cancer is also dominant among 
obese women (Chen and Russo 2009). According to Hortobagyi (2008), forty percent of 
inflammatory breast cancers are likely to be triple negative. TNBC is typically associated with 
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poor prognosis due to aggressive tumor phenotype(s), only partial response to chemotherapy, and 
present lack of clinically established targeted therapies (Podo and others 2010). As seen in Table 
2.2, TNBC subtype is highly heterogeneous in itself and is not one disease as it also has various 
subtypes (Adamo and Anders 2011; Oakman and others 2010).  
Table 2.2: Various Subtypes of TNBC 
Poor Prognosis 
Invasive ductal carcinoma NOS 
Invasive lobular carcinoma 
Metaplastic carcinoma 
Myoepithelial carcinoma 
High grade neuroendocrine (oat-cell) carcinoma 
Good Prognosis 
Apocrine carcinoma 
Medullary carcinoma 
Secretory breast carcinoma 
Adenoid cystic carcinoma 
Metaplastic carcinoma (adenosquamous and fibromatosis-like) 
 
The absence of expression of estrogen receptor, progesterone receptor, and HER2 (also 
referred to as ERBB2), and proving the worst outcomes with no therapeutic targets, makes the 
basal-like subtype of breast cancer one of relevance (Bosch and others 2010). Basal like breast 
cancer has characteristic features that include the triple negative phenotype however it has been 
stated that Triple Negative and Basal-like are not equivalent terms (Bosch and others 2010; 
Carotenuto and others 2010; Irvin Jr and Carey 2008; Oakman and others 2010). The term basal-
like breast cancer was coined to describe the tumors that overexpressed genes characterizing 
breast basal epithelial cells while triple negative is based on clinical observations describing 
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breast cancers that do not stain for ER, PR, and HER2 in immunohistochemistry studies (Bosch 
and others 2010).  
Research shows that patients with the basal-like subtype of breast cancer have poorer 
prognosis than patients with the Luminal subtype (Lorico and Rappa 2011). ER negative basal 
subtypes are associated shorter relapse and overall survival times with patients, than luminal ER 
positive subtypes (Rosen and others 2010). A study done with different breast cancer subtypes- 
luminal, ERBB2+, and basal-like showed shorter survival and overall disease-free survival with 
ERBB2+ and basal-like patients while it was longer for Luminal A subtype patients (Bosch and 
others 2010). The differences in survival could be explained by the overexpression of ERBB2 
(an oncoprotein) and presence of TP53 mutations which are associated with poor survival, as 
TP53 mutation levels were higher in ERBB2+ and basal-like types but not in Luminal A 
subtype. This shows that TP53 mutation is related to the lack of expression of ER and poor 
prognosis as seen in TNBC (Bosch and others 2010). 
TNBC patients are also associated with high or early relapse (Carotenuto and others 
2010; Chen and Russo 2009). TN tumors have worse relapse-free and overall survival for 
patients (Bosch and others 2010; Stratford and others 2010).  Women with TNBC are twice as 
likely as other women to develop distant metastases, causing a shorter survival in TNBC patients 
as this disease condition has high malignancy, poor differentiation and is very aggressive (Chen 
and Russo 2009). The lack of expression of ER, PR, and HER-2 makes treatment of TNBC 
difficult. Patients are mostly only treated with standard chemotherapy due to the lack of 
expression of ER, PR, and HER-2, preventing treatment with more specific targeted therapy 
(Chen and Russo 2009).  ER and PR were the first clinically used predictive prognostic markers 
for breast cancer arising from the exposition of hormonal regulation while HER-2 gene 
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amplification and protein over-expression have been the first cytogenic predictor for breast 
cancer treatment (Podo and others 2010; Rosen and others 2010).  
Estrogens are essential for normal growth and differentiation of human breast epithelial 
cells. However, exposure to excess estrogens for a prolonged time is an important etiological 
factor for the development of breast cancer. The presence of ER in breast tumors is used to 
predict response to endocrine therapies and disease prognosis. Progesterone and progesterone 
receptors are essential for estrogen promotion of breast cancer (Chen and Russo 2009).   
Human epidermal growth factor receptor (HER) is essential for normal breast growth and 
development and plays a key role in tumor development (Rosen and others 2010). Furthermore, 
gene-amplification and/ or over expression of HER-2 are key hallmarks in ER positive breast 
cancer patients (Alvarez and Price 2010; Chen and Russo 2009). It has been shown that HER-2 
over expression caused metastatic outgrowth of breast cancer cells in the brain (Chen and Russo 
2009). The HER family mediates a wide range of signals controlling various cellular process 
such as cell proliferation, angiogenesis, and apoptosis; however, HER2 is the preferred signaling 
partner for other members of the HER family (Rosen and others 2010). Thus, it serves as a great 
treatment target. The evaluation of HER2 overexpression guides in treatment selection and 
efficiency of treatment (Alvarez and Price 2010; Rosen and others 2010). Therefore, the absence 
of these essential breast cancer markers makes this disease very difficult to treat. 
Several features with breast cancer susceptibility gene (BRCA) outcome-associated 
breast cancer also occur with TNBC patients. For example, approximately 20% of breast cancer 
patients with mutations in BRCA-1 and BRCA-2 have deficiency in DNA repair because normal 
BRCA1 and BRCA2 have an important role in DNA repair (Bosch and others 2010; Chen and 
Russo 2009; Podo and others 2010). BRCA1 and BRCA2 gene mutations cause the disruption of 
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breast cell homeostasis which results in breast cancer. BRCA dysfunction can be an important 
mechanism in TNBC development (Bosch and others 2010). BRCA1 mutation is not only a 
prognostic marker, but also a predictive marker for chemotherapy response (Oakman and others 
2010).  
BRCA1 and BRCA2 play a role in cell-cycle control. The cell cycle is a series of 
coordinated events describing DNA replication and cell division (Collins and others 1997). The 
life cycle of the cells is divided in four phases based on DNA content and mitotic activity (Figure 
2.2). The cells divide in the M phase (mitosis), proceed on to the G1 phase with constant DNA 
content, and then into the S phase where DNA is duplicated. They enter the G2 phase from the S 
phase remaining at constant DNA content before going back into the M phase, continuing the 
cycle (McGuire and Dressler 1985). 
 
Figure 2.2: The cell cycle process 
BRCA1 and BRCA2 regulate tumor suppressor protein p53 activity which functions in 
DNA repair. When DNA repair is not possible, cells go into apoptosis, which is the process of 
programmed cell death and it is regulated by genetically directed pathways. Apoptosis plays a 
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role in the formation of tumors and makes cells resistant to treatment. The mechanism of 
apoptosis is avoided by cancer cells in order for them to thrive (Podo and others 2010; Rosen and 
others 2010; Siddiqa and Marciniak 2008). In other words, TNBC patients with problems in 
DNA repair make the mutation carriers more sensitive to DNA- damaging agents, leading to 
shorter survival and altered expression of a number of proteins, oncogenes, and abnormal 
signaling pathways in TNBC patients (Chen and Russo 2009).  
Though there is still a poorly understood association of TNBC with BRCA1 mutations 
(Podo and others 2010), there is definitely a significant overlap between TNBC, basal-like 
phenotype, and BRCA-1 mutated tumors (Oakman and others 2010). The heterogeneous 
characteristic of TNBC includes both basal and non-basal-like tumors, and triple negativity is 
sometimes used to identify basal-like tumors (Podo and others 2010). Only 71-91% of TNBC 
have basal-like phenotype, 77% of basal-like cancers are TNBC, while more than 80% of 
BRCA-1 mutations careers are triple negative (Chen and Russo 2009; Oakman and others 2010). 
In other words, not all BRCA-1 related breast cancers are TNBC or basal-like cancers (Bosch 
and others 2010). 
The pathogenesis of TNBC is still not known to a high extent. This is a major challenge 
in developing therapies effective for treating this type of cancer (Chen and Russo 2009). The 
buildup of defects at the levels of gene amplification, methylation, mutations and other cellular 
regulation mechanisms is the underlying cause for disease heterogeneity and differential 
response to treatment. Understanding the relations between potential TNBC markers may help to 
realize the heterogeneity of these tumors and improve the response prediction to both single 
agents and combination treatments (Podo and others 2010). It may not be likely that a single 
biomarker will provide reliable prognostic information for a patient. Multiparameter 
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technologies such as proteomic or gene expression analyses give high expectations and will be 
more productive than analyzing a single gene or protein (Alvarez and Price 2010). The patient 
and tumor characteristics and treatment outcomes of TNBC are summarized in Table 2.3. 
Table 2.3: Summary of clinical features of triple-negative tumors. 
Patient characteristics Younger age at diagnosis 
Predominantly African origin 
BRCA1 mutation carrier 
Tumor characteristics Ductal invasive carcinoma 
Rare histology (medullary, metaplastic) 
Negativity for ER, PR and HER-2 
Elevated mitotic count 
Tumor necrosis 
Highly invasive 
Larger tumor size 
Axillary node involvement 
Treatment/prognosis Chemosensitive 
No clinically established specific targets 
Poorer prognosis  
Aggressive relapse (trend of relapse 
within first 3 years) 
 
2.4. Angiogenesis and TNBC 
Angiogenesis is the formation of blood vessels from a pre-existing one and is an 
important process of tumoregenesis. (Auerbach and others 2003; Chen and Russo 2009). This 
process is an integral part of both normal developmental processes and numerous pathologies 
including inflammation and tumor growth (Auerbach and others 2003). It is essential for organ 
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growth and repair; however an imbalance in the process results in numerous malignant, 
inflammatory, infectious and immune disorders (Carmeliet 2005).  
The principal cells involved are endothelial cells which line all blood vessels and 
constitute virtually the entirety of capillaries. Figure 2.3 shows a summary of the angiogenesis 
process. For the formation of new blood vessels, endothelial cells must first break through the 
basement membrane, escaping from their stable location. Then the endothelial cells migrate 
toward an angiogenic stimulus (Auerbach and others 2003). Behind this migrating front, 
endothelial cells proliferate to form the necessary number of cells for making a new vessel, and 
then the new outgrowth of endothelial cells needs to reorganize into a patent three dimensional 
tube structure (Auerbach and others 2003).   
 
   Figure 2.3: Summary of angiogenic process 
Angiogenesis remains inactive during adulthood except in the cycling ovary and in the 
placenta during pregnancy. However, endothelial cells retain their ability to divide quickly in 
response to physicochemical stimulus such as hypoxia in blood vessels and in lymph vessels, and 
inflammation (Carmeliet 2005). In most disorders, this stimulus becomes excessive, resulting in 
an angiogenic switch due to an imbalance between stimulators and inhibitors. This is what 
occurs in most inflammatory disorders leading to additional processes responsible for diseases 
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such as obesity, asthma, diabetes, cirrhosis, multiple sclerosis, etc (Carmeliet 2005), whereas the 
stimulators are undersupplied in other situations causing the dysfunction of endothelial cells, 
vessel malformation or regression, or preventing healing and regeneration. Angiogenesis has 
been linked with over 70 disorders and the list is still growing (Carmeliet 2005).  
Angiogenesis does not initiate malignancy, but promotes tumor progression and 
metastasis as the tumor progresses from micrometastases to lethal macrometastases which is 
what mostly leads to death in cancer patients (Carmeliet 2005; Rosen and others 2010; Siddiqa 
and Marciniak 2008). The angiogenesis process is a fundamental mechanism in tumor growth 
and development into detectable masses (Bosch and others 2010; Rosen and others 2010). 
Angiogenesis plays a role in the aggressive IBC, TNBC. High VEGF, which is the key factor in 
angiogenesis, is correlated with poor prognosis and response (which are the main characteristics 
of TNBC). VEGF levels are a prognostic factor for relapse-free and overall survival in patients; 
in addition, PDGFR-α has been connected with aggressiveness (Carvalho and others 2005; Relf 
and others 1997).  Each step in neovascularization or angiogenesis, including the disruption of 
the basement membrane, cell proliferation, cell migration, and tube formation, can be a target for 
intervention (Auerbach and others 2003). Targeting just one step such as cell proliferation does 
not suffice in the formation of tumor mass (Rosen and others 2010). 
2.5. TNBC Associated Biomarkers  
Biomarkers are useful in the quantification of the course of malignancy and therapy 
response as well as in early identification of cancer patients and in therapy decision (Podo and 
others 2010). According to the U.S. Food and Drug Administration (FDA), a biomarker can be 
defined as “exploratory”, “probably valid” and “known valid”. A valid biomarker is “measured 
in an analytic test system with well-established performance characteristics, and for which there 
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is an established scientific framework or body of evidence that elucidates the physiologic, 
toxicological, pharmacological, or clinical significance of the test results” (Alvarez and Price 
2010). The success of biomarkers depends on: (1) our ability to reveal critical cancer related 
molecular events and the mechanisms of action of targeted therapy, and (2) the efficiency of the 
relationship of specific biomarker to another and to a certain disease condition (Podo and others 
2010).  
A number of molecular changes in IBC/ TNBC which contribute to the inherently high 
metastasis of IBC have been described (Charafe-Jauffret and others 2010). Some markers which 
have been demonstrated to be useful in IBC/ TNBC are p53 and Hsp90. These biomarkers are 
useful for the prognostic evaluations, and for therapeutic response predictions which provide 
guidance for patient management (Podo and others 2010).  
2.5.1. Breast Cancer Stem Cell Biomarkers 
There have been no markers demonstrated to predict systemic metastasis development in 
IBC, however, there is increasing evidence that human breast cancers are driven by cancer stem 
cells (CSC) which initiate tumors with self renewal properties. CSCs have recently been 
validated by different studies to be a small cell population resistant to current anticancer 
therapies, antimitotic agents, and radiation. CSCs have the ability to sustain tumor formation and 
growth, giving rise to multi-lineage differentiated cells which form the tumor (Charafe-Jauffret 
and others 2010; Lorico and Rappa 2011). They are referred to as tumor-initiating cells which 
are resistant to therapy, and have been said to be probably responsible for the early recurrence in 
TNBC (Stratford and others 2010).  
16 
 
There are various breast cancer stem cell biomarkers. The different breast cancer cell 
lines and primary tumors show differences in expression of these CSC. The main cancer stem 
cells associated with TNBC include CD44, epithelial specific antigen (ESA), and aldehyde 
dehydrogenase (ALDH1) (Hwang-Verslues and others 2009). 
2.5.2. TNBC Signal Transduction Biomarkers 
Various processes occur either simultaneously or sequentially in tumor cells, producing 
signals. Signals from the environment can also lead to conflicting stimuli. Therefore organization 
of the processes requires firm coordination of the process events. For example, proteins like p53, 
control the expression of a large numbers of genes (Podo and others 2010). Table 2.4 shows 
some biomarkers associated with TNBC tumor and patient characteristics and their biological 
effects as related to the disease.  
Table 2.4: TNBC associated biomarkers 
Biomarker Biological Effects 
           Akt Cell proliferation  
Cell growth 
           ERK /MAPK  Cell proliferation 
Increased migration and invasion 
Hsp90 Regulator of HER family 
Apoptosis  
P53 Apoptosis/ Defective DNA repair 
Cell proliferation/ Cell cycle 
Bax/ Bcl-2 Apoptosis 
VEGF Angiogenesis 
NFκB Inflammation 
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TNBC is known to have implications on cell signaling pathways, tumor metabolism, 
evasion of cell-cycle control, invasion, and metastasis. TNBC also affects a high number of 
genes associated with cell proliferation, frequent p53 mutations, reduced DNA repair capability, 
and increased angiogenesis (Oakman and others 2010).   
2.6. Treatment Options and Responses 
The main currently used treatment for breast cancer is chemotherapy. The cytotoxic 
effects of chemotherapeutic compounds occur by interference with DNA or RNA functions 
(Kitano 2004). It has been demonstrated that TNBC is a chemo-sensitive disease which escapes 
control by current standard treatments and with a lack of clinically established targets (Bosch and 
others 2010; Podo and others 2010). Some biological and chemotherapeutic agents are currently 
being tested either singly or in combination with other agents to increase treatment effectiveness. 
These agents directly target biomarkers associated with this highly metastatic breast cancer. 
Some treatment agents in trial are seen in Table 2.5. Though these therapies are being used, there 
are limitations and challenges being faced in using them. 
Table 2.5: Possible Agents for TNBC Targeted Therapies  
Biomarker/ Signal 
pathway 
Proposed therapeutic agents 
HER1 (EGFR) Cetuximab; Erlotinib; Gefitinib 
P53 Not available 
VEGF/VEGFR Bevacizumab; Sunitinib; Sorafenib 
AKT Perifosine 
ERK/ MAPK ERK kinase inhibitors 
Hsp90 Tanespimycin 
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One major challenge in the development of treatment for this disease is the heterogeneity 
and complexity of this disease. Most cancer drugs aim at a limited number of targets, however 
there are numerous metastatic channels or signal pathways associated with the hallmarks of 
cancer which are evading metastasis, self-sufficiency in growth signals, insensitivity to anti-
growth signals, limitless replicative potential, tissue invasion and metastasis, and sustained 
angiogenesis. A lot of time, money, plus difficulty are involved in the search for targets that are 
valid and crucial to the disease (Siddiqa and Marciniak 2008; Tian and others 2010).  
 More challenges in TNBC treatment include drug resistance, low survival rate 
improvements, restrictions on therapies to a subset of patient populations (Rosen and others 
2010) and low treatment success. The safety of anti-angiogenic treatment is a topic of emerging 
importance (Carmeliet 2005). It is a challenge to find the perfect targeted therapy that is specific 
for tumor cells without affecting the normal healthy tissues (Irminger-Finger 2010). One of the 
challenges is that chemotherapy or radiation can stimulate tumor initiating cells which could be a 
reason for early recurrence in TNBC. As a result of these challenges currently being faced with 
the treatment of this aggressive disease, new therapeutic agents are therefore being sought for 
TNBC (Stratford and others 2010).  
2.7. Functional Foods and Breast Cancer 
The present lack of efficacious clinically established targeted therapies demands a need 
for better prevention of IBC and TNBC. The currently used chemo-therapeutic agents have 
yielded low success rates with awful side-effects in breast cancer patients, leading to numerous 
studies on dietary components that will potentially be used in cancer prevention and treatment. 
Natural dietary compounds from foods will be less toxic to the human body than chemotherapy 
drugs (Lipski 2005). Lifelong dietary habits have a large influence on cancer development thus 
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dietary changes may prevent breast cancer development (Hanf and Gonder 2005; Tsubara et al. 
2005; Kotsopoulos and Narod 2005). 
Some of the various dietary components that have been and/ or are being studied for their 
anti-cancer activities are mentioned below. Resveratrol has been shown to have the qualities of 
natural chemo preventive agents including N-acetylcysteine, melatonin, reduced lipoic acid, and 
phytoestrogens (Chen and Russo 2009). Curcumin from turmeric has been shown to provide 
anti-inflammatory effects on biomarkers of IBC such as NF-κB and COX-2 (Jurenka 2009). 
Foods with polyphenolic compounds such as some mango varieties and cranberries have been 
studied for anti-carcinogenic effects on inflammatory breast cancer cells (Neto 2007; Noratto and 
others 2010). It has also been demonstrated that fenugreek has shown anti-cancer activities in the 
down-regulation of p53 (Shabbeer and others 2009). Oils from various food sources are also 
receiving focus in cancer prevention studies. For example, fish oil has been studied for its 
benefits in inhibiting tumor growth and progression (Mandal and others 2010).  
2.8. Black Seed  
One of the most expansively studied plants, as a result of the growing interest in naturally 
occurring compounds with anticancer potential, is Nigella Sativa known as Black Seed or Black 
Cumin Seed (Gali-Muhtasib and others 2006; Ramadan 2007). It is a dicotyledon grown in 
countries bordering the Mediterranean Sea, Pakistan, and India. The seeds have been used for 
thousands of years in a variety of foods such as bread, pastries, yogurt, pickles, soups, sauces, 
salad dressings, etc. It is also used externally on the skin or in cosmetics (Goreja 2003; 
Hajhashemi and others 2004).  
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It has been used for a very long time as a spice and food component, for its medicinal 
properties to promote health and prevent diseases, and to aid digestion (Ramadan 2007; Salem 
2005; Tauseef Sultan and others 2009). Black seed provides a good source of essential nutrients 
with a diverse chemical composition comprising essential fatty acids, amino acids, 
carbohydrates, fiber, and minerals such as calcium, iron, etc (Gali-Muhtasib and others 2006; 
Tauseef Sultan and others 2009). 
 
Figure 2.4: Black seed plant, black seed, black seed oil  
Black seed oil is the spicy yellowish oil with an aromatic flavor and fresh flavored odor 
extracted from black cumin seed (Hajhashemi and others 2004; Ramadan 2007). Thymoquinone 
(TQ) is the major anticancer bioactive compound in the oil extracted from black seed (Figure 
2.5) (Effenberger and others 2010; Gali-Muhtasib and others 2006; Hajhashemi and others 2004; 
Ramadan 2007; Velho-Pereira and others 2011).  
 
 
 
 
 
 
 
 Figure 2.5: Chemical structure of Thymoquinone 
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It has been shown both in vivo and in vitro that thymoquinone inhibits the proliferation of 
various human cancers. Combining TQ with anti-cancer drugs has improved the results of 
chemotherapy and reduced their damaging effects to normal cells. Animal models have been 
used in numerous studies to demonstrate the promising effects of black seed oil anti-cancer 
activities (Gali-Muhtasib and others 2006). Though thymoquinone is the major bioactive 
compound of this oil, it has been shown that various compounds in the oil such as thymoquinone, 
terpineol, and carvacrol, work synergistically. Thus the importance of using the whole oil in 
studies is stressed. Studies have shown that the seed extract has low levels of toxicity (Ali and 
Blunden 2003; Effenberger and others 2010)  
2.9. Potassium Chloride (KCl) 
Western –style diets portray high salt and low potassium content, but the promotion of 
low sodium diets is on the rise. It has been reported that reducing salt intake reduces the risk of 
breast cancers (Strnad 2010). Potassium chloride (KCl) is the most widely used salt alternative 
among other alternatives to sodium chloride (NaCl) salts (Naidu 2000; Samapundo and others 
2010). Potassium is an essential dietary component. It is also one of the essential minerals 
involved with cellular activities and heart stability in the body, at a normal range of 3.5-5.5 
mmol/L (Zehender and others 1997). It is one of the three major electrolytes in the body that 
maintains blood pH. It is absorbed through the small intestine and excess potassium is excreted 
by the kidneys (Weatherby and Ferguson 2002).  
One concern associated with potassium consumption is its toxicity level; however in 
normal conditions, the kidney functions in maintaining a normal potassium level in the blood. 
Thus, in a healthy population with normal kidney function, high potassium intake from foods 
poses no risk as the kidney readily excretes excess potassium. In contrast, overuse of 
22 
 
supplemental potassium can lead to toxicity in healthy individuals. The adequate intake of 
potassium has been set at 4.7g/day by an Institute of Medicine committee. Potassium intake of 
less than the adequate consumption amount is appropriate for individuals with impaired 
potassium excretion due to effects from hyperkalemia (Caballero 2009). Hyperkalemia occurs 
when elevated potassium levels surpass the amount the kidneys can excrete or when more than 
18g of potassium is consumed orally at one time (Wilcox and Tisher 2009). An advantage of 
potassium consumption is seen in the inverse relationship between dietary potassium and blood 
pressure as an increase in daily consumption of potassium by 0.78g reduced blood pressure in 
hypertensive patients (D'Elia and others 2011). 
Another concern with the consumption of potassium chloride is its flavor. It has a salty 
taste. However, when consumed in high amounts, KCl can impart bitterness and a metallic 
aftertaste. Since KCl provides sodium reduction advantages, it is blended with other ingredients 
to reduce its bitterness when used in formulations. Some KCl blends that have been used to 
reduce or eliminate the bitter taste from KCl include yeast; monopotassium glutamate, potassium 
citrate, potassium phosphate, L-glutamic acid, silicon dioxide, and KCl (Naidu 2000). Also, 
methyl and ethyl maltol which are mouth-feel enhancing ingredients mask the bitter taste of KCl 
in seasoned foods. Amino acids and organic acids are also said to reduce the bitterness of KCl 
when precipitated from aqueous solution (Roy 1997). 
The anti-cancer activity of KCl is linked with the apoptotic activity of heat shock proteins 
(such as Hsp90) in the disease. Hsp90 is a chaperone protein which functions as a regulator of 
the HER family. Hsp90 is over-expressed in human tumor cells by up to ten fold due to ATPase 
activity. ATPase activity with Hsp90 has been proven to be reduced by KCl at 0.4% both in vivo 
and in vitro (Kamal and others 2003; Rosen and others 2010).  
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With the recent trend in using KCl as a substitute to NaCl in promoting low sodium diet, 
not many studies have been done showing the effects of KCl on cancer cells. To the best of our 
knowledge, no study has been done to see the effect of black seed oil combined with KCl on 
breast cancer cells. It is expected that the combination of KCl with black seed oil will enhance 
the inhibition activity of these dietary compounds against the highly aggressive TNBC.  
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CHAPTER 3: 
MATERIALS AND METHODS 
3.1. Cell Lines and Reagents 
Breast cancer cell line MDA-MB-231 was obtained from American Type Culture 
Collection (ATCC, Manassas, VA). The cell line was propagated in Dulbecco’s Modified 
Eagle’s Medium (DMEM) high glucose containing sodium bicarbonate, 15 mM HEPES, fetal 
bovine serum to a final concentration of 10%, and nonessential amino acids. Cell propagation 
media were from Invitrogen (Carlsbad, CA). Protease inhibitor cocktail was purchased from 
Sigma Co (St. Louis, MO). Cold pressed extracted black seed oil was purchased from Botanic 
Oil Innovations (Spooner, WI). Electrophoresis gels and reagents, and PVDF membranes were 
from Invitrogen (Carlsbad, CA). Potassium chloride was purchased from EMD Chemical 
(Gibbstown, NJ). Primary antibodies (ALDH1, CD44, ESA, p-ERK, p53, NF-κB, Bax, and Bcl-
2) and all secondary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA). Primary antibody (p21) was from Fisher Scientific (Fremont, CA).  COX-2 was from 
Cayman Chemical Company (Ann Arbor, MI). Primary antibody p-Akt was from Cell Signaling 
Technology (Danvers, MA). Hsp90α was from Abcam (Cambridge, MA). All other reagents 
were of analytical grade.  
3.2. Gas Chromatography Analysis on Black Seed Oil 
 The gas chromatography profile for black seed oil in this study was obtained by analysis 
on a Leco TOF GC/MS system equipped with an Agilent 6890 GC.  A DB-5 (J &W Scientific, 
Albany, NY) 30 m by 0.25 mm I.D. with a 0.25 μm film thickness was used with a flow rate of 
1.0 mL/min.  One microliter injections were made in splitless mode at an injection temperature 
of 300 °C.  The GC oven was initially held at 50 ºC for one minute then increased at 3 ºC/min to 
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80 °C and then at a rate of 10 °C/min to 340 °C.  The mass spectrometer was operated in electron 
impact mode at 70 eV.  Data was collected from m/z 35 to m/z 1000 and stored at 20 
spectra/sec.   
3.3. Cell Viability and Proliferation Assay 
 MDA-MB-231 cells (1 x 10
4
 cells/well in 100 μL) were seeded in 96-well plates to 
adhere overnight. BSO, KCl, or BSO with KCl were prepared as stock solutions (BSO was 
prepared in DMSO and diluted in the cell culture media to achieve a final DMSO concentration 
of less than 0.1% in each well or plate used in this study).  The BSO treatment ranged from 0-
0.22% BSO per media solution. KCl treatments ranged from 0-0.2% KCl, the KCl was directly 
dissolved in cell culture media and pipetted on to cells in 96-well plates before incubation. The 
combination treatments were done with 0.22% BSO and concentrations of KCl from 0-0.2% 
KCl.  The 96-well plates were incubated in the presence or absence of treatments followed by 
stimulation with 100 ng/mL of IGF-I and additional incubation for 24 h, 48 h or 72 h in serum-
free medium at 37 °C, 5% CO2 in a humidified incubator. After incubation, cell viability was 
determined by MTS assay. CellTiter 96 AQueous One solution (Promega, Madison, WI) was used 
following the MTS Assay protocol from Promega. 20μl of the MTS solution was added to each 
well before incubation in a humidified 5% CO2 incubator at 37
0
C for a minimum of one hour. 
The absorbance was read at 490 nm using a Bio-Rad Model 680 micro plate reader (Hercules, 
CA). The percentage of surviving cells were determined by reduction of MTS [(3-(4, 5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-trazolium, innersalt)]. 
Cell viability was normalized to the levels in untreated control cells to determine the percentage 
of viable cells. Each experiment was performed in triplicate.  
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3.4. Cell Cycle Analysis by Flow Cytometry 
The technique of clinical flow cytometric DNA was done using the florescence activated 
cell sorter (FACS), a flow cytometer that rapidly measures the fluorescence intensity based on 
DNA content of a cell population that has been stained with a fluorescent DNA dye (Morgan 
2007).  Cells were seeded at a density of 2.5 x 10
6 
cells in T-25 flasks overnight, and treated with 
0.22%  BSO (using DMSO as a vehicle), or KCl at 0.2 % , or the combination of 0.22% BSO 
and 0.2% KCl for 72 h. To analyze the cell cycle after treatment period, cells were harvested by 
trypsinization, washed with PBS, and stained using the Beckman-Coulter DNA Prep Reagents 
Kit (cat # 6607055) following the manufacturers recommended staining procedure. Aliquot of 
cells were first incubated and vigorously vortexed for 30 s with reagent 1 (RNase and detergent) 
and stained for 1 h in the dark with reagent 2 (propidium iodide). The stained cells were read on 
a Beckman-Coulter Epics FC500 flow cytometer using CXP software for the initial acquisition. 
The data were then modeled using ModFit LT v3.2 software from Verity Software House 
(Topsham, ME). 
3.5. In vitro Angiogenesis 
The Angiogenesis Assay kit was obtained from Chemicon (Temecula, CA). Human 
umbilical vein endothelial cells (HUVEC) were used for this assay. The gel matrix was prepared 
following the manufacturer’s instructions and then incubated at 37˚C to allow the matrix solution 
to solidify. HUVEC at 1 x 10
4 
cells per well were seeded onto the surface of polymerized 
ECmatrix (Chemicon, Temecula, CA) alone, or treated with 0.22% BSO, or 0.2% KCl, or the 
combination treatment (0.22% BSO/0.2%  KCl). The plate was then incubated at 37˚C for 6h. 
Tube formation was then inspected under an inverted light microscope (Olympus IX50) and 
photographed. 
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3.6. Total Cell, Cytoplasmic, and Nuclear Extracts Preparation and Protein Determination 
Treated cells were grown as monolayer on T-75 flasks. Total cell extracts were prepared 
as follows. Briefly, cells (1 x 10
7
 cells) were treated with DMSO as vehicle, BSO, or KCl, or the 
combination of BSO and KCl, washed with PBS, collected by scraping with RIPA buffer (50 
mmol/L Tris-HCl, 150 mmol/L K NaCl, 1% Nonidet P-40,
 
0.5% sodium deoxycholate, 0.1% 
SDS, PMSF, orthovanadate, protease inhibitor mixture (added at a 1:100 dilution)) and incubated 
at 4 °C for 30 min. Lysates were centrifuged at 14,000 x g for
 
10 min and the supernatant 
recovered in other Eppendorf test tubes. Aliquots of supernatants were stored at -80 ºC for 
Western blot.  
Cytoplasmic and nuclear extracts were prepared as follows. Briefly, cells were washed 
once with PBS and collected by scraping in 500 μL of hypotonic buffer (10 mmol/L HEPES pH 
7.9, 1.5 mmol/L
 
MgCl2, 10 mmol/L KCl, 0.2 mmol/L PMSF, 0.5 mmol/L DTT, 5 mmol/L NaF, 1 
mmol/L Na3VO4). Swollen cells were vortexed to shear cytoplasmic membranes. The mixture 
was centrifuged at 14,000 x g for 30 seconds and the supernatant was retained as cytoplasmic 
extracts. The nuclear pellet was resuspended in 50 μL of high-salt buffer (20 mmol/L HEPES pH 
7.9, 25% glycerol, 1.5
 
mmol/L MgCl2, 1.2 mol/L KCL, 0.1 mmol/L EDTA, 420 mmol/L NaCl, 
0.5 mmol/L DTT,
 
and 0.2 mmol/L PMSF) by pipetting up and down, vortexed 10 s at high 
setting, incubated for 30 min on ice, vortexed for 30 s at high setting, and centrifuged for 10 min 
at 14,000 x g in a micro-centrifuge pre-cooled at 4ºC. The supernatant (nuclear fraction) was 
transferred into other Eppendorf test tubes. Aliquots were kept at -80 ºC until use. Total protein 
in total cell extracts, cytoplasmic, or nuclear
 
fractions was determined by the DC Protein assay 
(Bio-Rad, Hercules, CA). 
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3.7. Western Immunoblot  
  Equal amounts (50 µg) of cytoplasmic or nuclear fractions from treated cells were diluted 
with LDS sample buffer (Invitrogen, Carlsbad, CA), boiled, and loaded onto 4-12% Bis-Tris 
gels. Proteins were separated and transferred to PVDF membranes. Membranes were
 
blocked 
with 5% BSA in TBS/Tween 20 (0.05%) following instructions from the antibody supplier, 
followed
 
by an overnight incubation with a primary antibody in 5% BSA in TBS/Tween20 
following the manufacturer’s suggestion. Primary antibodies for stem cell surface markers 
including ALDH1, ESA, and CD44 were analyzed. Primary antibodies associated with cell 
proliferation including p-Akt, p-ERK, NFκB and COX-2 were also analyzed and furthermore, 
we analyzed Hsp90α and some of its co-chaperone proteins including p53, p21, Bax, and bcl-2. 
Visualization of the bound primary antibody
 
was done by probing with alkaline phosphatase-
conjugated
 secondary antibodies following the manufacturer’s suggestion and exposure to 
chromogenic detection
 
reagent BCIP.
  
 
3.8. Statistical Analysis 
Statistical analysis was conducted using the Statistical Package for the Social Sciences 
(SPSS) software (version 15.0, 2006, SPSS Inc., Chicago, IL). Analysis of variance (ANOVA) 
was conducted to examine the differences between treatments followed by post-hoc analysis 
(LSD). A P-value of < 0.05 was considered to be statistically significant.  
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CHAPTER 4: 
RESULTS AND DISCUSSION 
4.1. Gas Chromatography-Mass Spectroscopy (GC-MS) Profile of Black Seed Oil 
 To determine the chemical profile of BSO, gas chromatography-mass spectrometric 
analysis was performed on the oil. The results of GC-MS analysis of BSO indicated the presence 
of thymoquinone, p-cymene, carvacrol, terpinolene, longifolene, hexadecanoic (palmitic) acid, 
and linoleic (octadecanoic acid) as major compounds in the oil (Table 4.1). Black seed oil is a 
vegetable oil rich in bioactive compounds. The strong neutraceutical potential of black seed has 
been ascribed to its rich phytochemistry (Tauseef Sultan and others 2009).  
Thymoquinone has been identified as the major bioactive component of black seed oil 
among other compounds that have been identified in the oil (Effenberger and others 2010; Gali-
Muhtasib and others 2006; Velho-Pereira and others 2011). The concentration of TQ in the oil 
used for this study was 25.2 g/kg of oil. Thymoquinone has been demonstrated both in vivo and 
in vitro to possess anti-inflammatory and anti-oxidant characteristics, and to  inhibit the 
proliferation of various human cancers (Gali-Muhtasib and others 2006; Salem 2005; Velho-
Pereira and others 2011). For the study of the interactions of BSO and TNBC cells in vitro, 
0.22% BSO containing 60 μM TQ was selected. 
Thymoquinone works synergistically with other compounds in the oil such as carvacrol 
(which is a phenol), and terpenes (such as p-cymene, terpineol). Terpenes have been found to 
improve absorption and therefore aid absorption of black seed oil by the body (Harrewijn and 
others 2001). Carvacrol is a phenolic compound which serves as an excellent natural antioxidant 
in spices (Peter 2004). The bioactive compounds such as terpenes and phenols in black seed oil 
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are responsible for the pharmacological properties associated with the oil (Bhattacharjee and 
Sengupta 2009). 
Table 4.1: GC-MS Profile of Black Seed Oil 
 
Peak No. RT Area % Library/ ID Ref # CAS# 
1 6.47 3.87 5- Isopropyl-2-methyl-1,3-cyclohxadiene 32141 000099-83-2 
2 9.38 16.60 p-cymene 31918 025155-15-1 
3 11.98 2.14 Terpinolene 31925 000586-62-9 
4 12.25 0.90 Decamethylcyclopentasiloxane 313067 000541-02-6 
5 14.33 23.11 Thymoquinone 64415 000490-91-5 
6 14.87 1.43 Morphinan-6-ol 290923 006703-27-1 
7 14.97 0.73 Carvacrol 46681 000499-75-2 
8 16.30 1.43 Longifolene 121403 000475-20-7 
9 16.62 1.53 1-Methyl-3-(3,4-dimethoxyphenyl)-6,7-
dimethoxyisochromene 
291787 093772-22-6 
10 18.02 1.11 3-(4-chlorophenyl)-4,6-dimethoxy-1-(prop-
2’-enyl)indole-7-carbaldehyde 
302379 000000-00-0 
11 19.00 0.68 6-octenal, 3,7-dimethyl 52561 000106-23-0 
12 19.18 0.63 Trisiloxane, 1,1,1,5,5,5-hexamethyl-3,3-
bis[(trimethylsilyl)oxy] 
322218 003555-47-3 
13 20.21 0.46 Octamethyl-cyclotetrasiloxane 244218 000556-67-2 
14 20.59 0.64 n-Hexadecanoic acid 195432 000057-10-3 
15 20.7 1.15 13-isopimaradiene 216672 001686-56-2 
16 21.45 3.76 Endo-2,2,3-trimethylbicyclo[2.2.1]heptane 34362 020536-40-7 
17 21.78 20.72 Linoleic acid 226097 000060-33-3 
18 21.96 8.98 1H-Purin-6-amine[(2-flourophenyl)methyl] 177443 074421-44-6 
19 24.82 10.11 2-chloro-4-(2’-furanyl)-6-(2’-
thienyl)pyrimidine 
202067 000000-00-0 
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The oil consists of several fatty acids of which over 80% are unsaturated fatty acids. The 
main fatty acids are linoleic acid, oleic acid, margaric acid,  cis-11,14-eicosadeinoic acid, and 
stearic acid (Amin and others 2010; MM and others 2011). The saturated free fatty acids in black 
seed oil have been shown to induce apoptosis (Mu and others 2001). The absence of triglycerides 
as observed in the GC-MS profile of this oil (Table 4.1) is an essential aspect of the nutritional 
value of the oil. Breast cancer occurs less often in Asian countries such as India and China where 
black seed oil is included in diet that in western countries such as the United States where black 
seed oil is not popularly consumed (Lyn 2011). 
 
4.2. Black Seed Oil or KCl or BSO with KCl Inhibits TNBC Cell Viability  
To determine the efficacy of BSO or KCl or BSO with KCl against TNBC cells, MDA-
MB-231 viability was screened in the presence of 0-0.22% of BSO or KCl at 0-0.2% or their 
combinations. MDA-MB-231 breast cancer cell line was used for this study. It was isolated from 
pleural effusion of a breast cancer patient. This cell line is well defined in its growth with 
invasive and metastatic characteristics. MDA-MB-231 cell line depicts triple negative 
characteristics of being ER, PR, and HER-2 negative (Bachmeier and others 2007). The cells 
have mesynchymal cell characteristics such as a strong ability to migrate (Yu and others 2009).   
The measurement of cell viability is used to study integrated cellular changes. Cell 
viability is simply the determination of the total number of live cells in a sample. This assay is 
applied in the evaluation of treatment effectiveness against cancerous cells. Cell viability 
determines the change in the total number of cells before and after treatment (Wu 2010).  
The MTS solution used for this analysis reacts with the cells in media solution producing 
a color change and the percentage of viable cells is relative to the color intensity of the cells in 
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media solution when read with a micro plate reader. BSO treated cells were reduced to 
approximately 20% at the highest concentration of treatment (0.22%) which contained 60µM TQ 
(Figure 4.1). Preliminary studies done in the lab showed that TQ at 60µM significantly reduced 
the percentage of viable cancer cells. In comparison to other concentrations of BSO used in this 
study (0.07% and 0.15%), the highest concentration of 0.22% was more effective. Also, the 
highest percentage reduction of viable MDA-MB-231 cells was observed after treatment for 72 h 
in comparison to 24 and 48 h of treatment. Therefore, we used 0.22% and 72 h treatment for all 
further analyses.  
 
Figure 4.1: Viability of Control and BSO treated MDA-MB-231 cells 
 
   
Figure 4.2: Viability of Control and KCl treated MDA-MB-231 cells 
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Figure 4.3: Viability of Control and BSO with KCl treated MDA-MB-231 cells 
 
TNBC cells were also treated with 0.05, 0.1, and 0.2% KCl per media solution. The 
percentage of viable TNBC cells reduced with increased treatment time and concentration of 
KCl (Figure 4.2). After treatment with 0.2% KCl for 72 h, the percentage viable cells were 
reduced to 19%. There were only slight differences between the different concentrations of KCl 
in their percentage reduction of viable cells. The most effective treatment concentration and 
time, 0.2% KCl and 72 h, were selected for further analyses.  
For the combination treatments 0.22% BSO per media solution was combined with three 
different concentrations of KCl (0.05, 0.1, and 0.2% KCl). A similar trend as with KCl 
treatments was observed as in increased reduction in percentage viable cells with increased 
treatment time and concentration of KCl (Figure 4.3).0.22% BSO combined with 0.2% KCl 
reduced percentage viable cells to approximately 27%, while treatments with 0.1 and 0.05% 
showed reduction to 34 and 37% viable cells respectively. BSO with 0.2% KCl which showed 
highest reduction in percentage viable cells was selected for further analyses. 
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4.3. Black Seed Oil or KCl or BSO with KCl Alters TNBC Cell Cycle Progression 
To determine whether BSO or KCl or BSO with KCl induced reduction in TNBC cell 
viability was associated with cell cycle perturbation, cell cycle analysis by flow cytometry was 
performed and the distribution of cells in different phases of the cell cycle at 72 h of treatments 
was measured. Cell cycle analysis can be used for cell activation and proliferation measurement. 
Flow cytometry is used to determine cancer prognosis as abnormal DNA content would indicate 
high risk for tumor recurrence and worse prognosis (Hedley and others 1987). 
The TNBC cells were fixed with methanol and stained with propidium iodide (PI). The 
PI intercalates into double stranded nucleic acids and can be excited by 488-nm lasers. The 
enzyme RNAse is used for degradation of double stranded RNA so that only double stranded 
DNA is left within the cell to bind to PI. When DNA binds to PI, florescence increases and PI 
peaks can be emitted. Flow cytometry analysis gives the percentage of cells in the phases of cell 
cycle (G0/G1, S, AND G2/M). Cell cycle analysis histograms report the G2 and M phases as 
combined in view of the fact that they cannot be distinguished on DNA content basis. 
After analysis of control and BSO or KCl or BSO with KCl treated TNBC cells, it was 
observed that BSO treated MDA-MB-231 cells accumulated in the S-phase (from 6.24% in 
control cells to 27.28% in BSO-treated cells) and increased cells in G2/M phase while there was 
a decrease in G1 (Figure 4.5). The BSO with KCl combination treatment showed similar effect 
in cell population as the BSO- treated cells. The combination treatment showed an accumulation 
in the S phase with an increase from 6.24 in control to 17.4%, an increased population of cells in 
the G2/M phase and a decrease in the G1 phase (Figure 4.7). KCl treated cells also accumulated 
in the S phase with 21.58% and reduced in the G1 phase but showed a decrease in the G2/M 
phase (Figure 4.6).                                                                   
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Figure 4.4: Flow cytometry histogram for MDA-MB-231  
 
 
 
 
Figure 4.5: Flow cytometry histogram for BSO treated MDA-MB-231 
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Figure 4.6: Flow cytometry histogram for KCl treated MDA-MB-231 
 
 
 
 
 
 
Figure 4.7: Flow cytometry histogram for BSO with KCl treated MDA-MB-231 
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In conditions where there is adequate supply of nutrients, cell proliferation can occur. 
This usually takes place by default in the G0 phase for most non-tumorigenic cells and this is 
well controlled. However, genetic defects affect the cell cycle in cancer and lead to an 
uncontrolled cell division which is a hallmark of cancer. In most cancer cells, the control of 
progression in cell cycle is faulty, allowing cells with DNA errors (as with TNBC) to progress on 
to the next phase of the cycle. The cancer cells disregard cell cycle control and remain in the 
cycle causing more genetic diversity (Podo and others 2010). However based on the results 
obtained with treated cells, there was increased number of cells in the S phase in comparison to 
the control cells showing that BSO or KCl or BSO with KCl treatments interfere with the cell 
cycle progression machinery at the reputed S phase restriction point or checkpoint.  
 
4.4. Black Seed Oil or KCl or BSO with KCl Inhibits Endothelial Cell Tube Formation 
 To determine the effect of BSO or KCl or BSO with KCl on endothelial cell tube 
formation, an in vitro angiogenesis tube formation assay was performed. Each of the steps in 
angiogenesis, including basement membrane disruption, cell migration, cell proliferation, and 
tube formation can be an intervention target and can be tested in vitro. Tube formation 
angiogenesis assay is a very specific test used for angiogenesis (Auerbach and others 2003). On a 
synthetic basement membrane matrix, cells are capable of morphological differentiation
 
into an 
extensive network of capillary-like structures composed
 
of highly organized three-dimensional 
cords. According to Bansode (2011), the alignment of endothelial cells in capillary-like 
structures is a functional trait that is crucial to angiogenesis.  
 In this assay, the ability of endothelial cells to form three-dimensional tubular structures 
was observed under a microscope. In the presence of 10ng/ml of VEGF, human umbilical vein 
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endothelial cells (HUVEC) plated on the EC matrix aligned and formed capillary-like three 
dimensional structures within 6h (Figure 4.8a). BSO or KCl or BSO with KCl inhibited tube 
formation within 6h. Treatment with BSO or KCl or BSO with KCl completely disrupted the 
capillary-like network of the ECmatrix (Figures 4.8b-d). 
                    
(a) Control HUVEC                (c)  BSO treated cells 
             
(b) KCl treated cells      (d) BSO with KCl treated cells 
Figure 4.8: Control and BSO-, KCl-, and BSO with KCl- treated HUVEC 
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4.5. Black Seed Oil or KCl or BSO with KCl Down Regulates the Expression of Breast  
Cancer Stem Cell Markers 
To further determine the molecular mechanism associated with BSO- or KCl- or BSO 
with KCl- mediated anti-proliferation activity on MDA-MB-231 cells, some relevant 
overexpressed or activated signaling proteins in the TNBC cells were investigated. Protein 
expression levels were determined by western blot analysis. Gene expression levels of breast 
cancer stem cell markers were analyzed.  
There have been no markers demonstrated to predict systemic metastasis development in 
TNBC; however, there is increasing evidence that human breast cancers are driven by cancer 
stem cells (CSC), which initiate tumors with self renewal properties (Charafe-Jauffret and others 
2010). CSCs have been validated by different studies to be a small cell population resistant to 
current anticancer therapies, antimitotic agents, and radiation. They are referred to as tumor-
initiating cells which have been said to be probably responsible for the early recurrence in TNBC 
due to their resistance to therapy. The ability of CSCs to sustain tumor formation and growth 
gives rise to multi-lineage differentiated cells, which form the tumor (Hwang-Verslues and 
others 2009; Lorico and Rappa 2011).  
There are various breast cancer stem cell biomarkers, different breast cancer cell lines 
and primary tumors show differences in expression of these CSC (Hwang-Verslues and others 
2009). CD44, aldehyde dehydrogenase (ALDH1), and epithelial specific antigen (ESA) have 
been recognized as triple negative breast CSC. CD44
+
/CD24
- 
phenotype have shown high 
capacity for tumor initiation and for expression of ESA which is known to be a cell surface 
marker. ALDH is an enzyme involved in stem cell self-protection; tumors positive for ALDH 
expression have been associated with a lack of expression of ER and PR, and a poor clinical 
outcome (Croker and others 2009; Stratford and others 2010). BSO or KCl or BSO with KCl 
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down regulated the expression of TNBC cell surface markers including ALDH1, CD44, and 
ESA (Figure 4.9).  
Ctrl BSO 
0.1% 
KCl 
0.2%
KCl 
BSO/ 
0.2% KCl 
 
ALDH1   
        
   CD44     
         
     ESA     
          
Figure 4.9: BSO or KCl or BSO with KCl treatments down regulate the expression of 
TNBC stem cell markers 
 
4.6. Black Seed Oil or KCl or BSO with KCl Affects the Activation of Signaling Pathways 
Associated with Cell Proliferation and Metastasis 
To determine the molecular mechanism associated with BSO or KCl or BSO with KCl 
mediated anti-proliferation activity on TNBC cells, some relevant overexpressed or activated 
apoptotic and cell survival signal transduction pathways associated with TNBC cells were 
evaluated. Cell proliferation in TNBC is stimulated by the phosphatidylinositol-3 kinase 
(PI3K)/Akt and/or the extracellular signal-regulated kinase (ERK) signaling pathways. BSO or 
KCl or BSO with KCl inhibited PI3K pathway and suppressed the phosphorylation of Akt, or 
ERK in MDA-MB-231 cancer cells (Figure 4.10). PI3K/Akt and NF-κB signaling pathways have 
been shown to be signaling pathways associated with the growth, migration, invasion, 
angiogenesis and metastasis in cancer progression (Rangaswami and others 2004; Wang and 
others 2009). The PI3K/Akt pathway promotes cell proliferation and survival by modulating 
several downstream signaling proteins including NF-κB. Results show that BSO or KCl or BSO 
with KCl down-regulated the levels of NF-κB in TNBC cells (Figure 4.10). Cyclooxygenase 
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(COX)-2 an inflammation marker associated with TNBC was also down-regulated by the 
treatments used in this study. Anti-inflammatory properties of black seed oil have been 
demonstrated in vivo and in vitro, and it was observed that the inflammation pathway 
cyclooxygenase (COX) was inhibited (Salem 2005). It is conceivable that COX-2 down-
regulation was associated with the inhibition of NF-κB because the promoter sequence of COX-2 
contains binding sites for NF-κB (Kaltschmidt 2002).        
Ctrl BSO 
0.2% 
KCl 
BSO/ 
0.2% KCl 
 
p-Akt      
   
p-ERK      
   
NF-κB       
   
COX-2      
   
Figure 4.10: BSO or KCl or BSO with KCl treatments down regulate cell proliferation and 
progression markers 
 
4.7. Black Seed Oil or KCl or BSO with KCl Affects the Activation of Signal Transduction 
by Hsp90 and Client Proteins  
To determine whether BSO or KCl or BSO with KCl inhibits Hsp90 activity, Western 
blot analysis of Hsp90α was performed on MDA-MB-231 cells treated with BSO or KCl or BSO 
with KCl. Hsp90 has been recognized as a master regulator of signal transduction (Boulon and 
others 2008). Hsp90 is highly expressed in TNBC cells and assists in the conformational 
maturation and stability of a range of “client proteins”. The overexpression of Hsp90 is mainly 
due to ATPase activity as the chaperone activity of Hsp90 is dependent on the activity of this 
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enzyme. Most Hsp90 client proteins are frequently mutated and include key mediator factors that 
regulate cell proliferation, inhibit apoptosis, regulate cell cycle, enhance inflammation, and 
sustain the survival of cancer cells. Inhibition or interruption of Hsp90 can destabilize these 
client proteins and lead to cancer cell apoptosis. The clinical significance of Hsp90 is that many 
of its client proteins are overexpressed in several types of cancer progression and proliferation 
including TNBC (Bagatell and Whitesell 2004; Kang and others 2010). Inhibiting Hsp90 
disrupts Hsp90 interactions with co-chaperones and leads to the degradation of client proteins 
and weakening of processes fundamentally important to cancer cells including proliferation, cell 
cycle regulation, and avoidance of apoptosis (Powers and Workman 2006; Zhang and others 
2008; Zuehlke and Johnson 2010).  
Ctrl BSO 
0.4% 
KCl 
BSO/ 
KCl 
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Figure 4.11: BSO or KCl or BSO with KCl treatments inhibit activity of Hsp90 and other 
apoptotic markers 
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Western blot analysis indicated that the expression of Hsp90α was down-regulated in all 
treated cells (Figure 4.11).  The anti-cancer activity of KCl is linked with the apoptotic activity 
of heat shock proteins in the disease. ATPase activity with Hsp90 has been proven to be reduced 
by KCl at 0.2% both in vivo and in vitro (Kamal and others 2003). 
The focus for this study was on Hsp90α, p53, NF-κB, bax, and bcl-2, because Hsp90 
chaperones most of these proteins. Apoptosis induction is mediated by these proteins. Results in 
Figure 4.11 indicate that the levels of mutated p53 in BSO- or KCl- or BSO with KCl -treated 
TNBC cells were reduced compared to control cells. Thymoquinone from BSO is known to 
induce apoptosis by p53 pathways in cancer cell lines (Gali-Muhtasib and others 2006). The 
tumor suppressor protein p53 is a critical component of the apoptotic pathway as it controls the 
expression of large numbers of genes. P53 is mutated and non functional in most tumors and has 
been associated with poor prognosis of most cancers including TNBC. Due to a defective cell 
cycle, frequent p53 mutations have been reported in TNBC cells (Oakman and others 2010; Podo 
and others 2010). BSO or KCl or BSO with KCl decreased the levels of mutated p53 in MDA-
MB-231 cells. However it was shown that KCl alone and the BSO/KCl combination treatments 
were more effective than BSO alone in down-regulating the expression of p53. A similar 
observation was made with p21, as it was also down-regulated in treated MDA-MB-231 cells. 
The Bcl-2 family which includes both proapoptotic proteins such as Bax and 
antiapoptotic proteins such as Bcl-2 are associated with the regulation of cell growth and 
apoptosis. Overexpression of Bcl-2 enhances cell survival by apoptosis suppression on the other 
hand, Bax overexpression speeds up death (Wang and others 2009). Studies have shown that 
thymoquinone from black seed oil inhibits anti-apoptotic Bcl-2 (Ait Mbarek and others 2007). 
The levels of Bax proteins remained almost unchanged suggesting cell death by mixed apoptotic 
44 
 
and non-apoptotic ways. Down-regulation of Bcl-2 expression suggested that cell death occurred 
by apoptosis. The down-regulation of bcl-2 is likely linked to the ability of the treatments to 
induce apoptosis in TNBC cells. It was observed that bcl-2 levels were down-regulated by all 
treatments used (BSO or KCl or BSO/KCl). However unlike BSO and the BSO/KCl combination 
treatment, KCl treated cells did not show up-regulation of Bax as should be the case for effective 
induction of apoptosis. This shows an advantage of the combination treatment over the use of 
KCl alone. 
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CHAPTER 5: 
SUMMARY AND CONCLUSION 
The main objective of this study was to investigate the interaction of black seed oil 
(BSO) or potassium chloride (KCl) or a combination of the oil with potassium chloride with the 
biomarkers of triple negative breast cancer. To test this objective, the major bioactive compound 
in black seed oil, thymoquinone, was identified in the commercially available oil used for the 
study and cell viability, cell cycle, in vitro angiogenesis tube formation assays, as well as western 
immunoblots on TNBC associated biomarkers were performed to examine treatment effects on 
different aspects of TNBC. The expected results were that the treatments would inhibit the 
proliferation and anti-apoptotic activity of TNBC cells. 
The results prove that black seed oil or KCl or BSO with KCl treatments inhibited the 
viability of MDA-MB-231 triple negative breast cancer cells after 72h exposure and led to down-
regulation of several factors associated with cell proliferation and apoptotic signal transduction 
including Hsp90. Also the treatments disrupted tube formation in angiogenesis, and caused an 
interruption in TNBC cell cycle progression. This shows that the treatments were effective in 
targeting the hallmarks of breast cancer and characteristics of TNBC. 
Overall, the analyses performed demonstrate that black seed oil and potassium chloride 
have a strong potential and several advantages as preventive or therapeutic agents for this 
aggressive deadly disease, triple negative breast cancer. However, further studies should be done 
to examine the interaction of these anticancer agents in vivo. 
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